EXMceuticals (FRA:9OM1) Debt-to-Equity : -0.65 (As of Mar. 2021)

View and export this data going back to 2015. Start your Free Trial

What is EXMceuticals Debt-to-Equity?

EXMceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was €0.69 Mil. EXMceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was €0.01 Mil. EXMceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2021 was €-1.09 Mil. EXMceuticals's debt to equity for the quarter that ended in Mar. 2021 was -0.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for EXMceuticals's Debt-to-Equity or its related term are showing as below:

FRA:9OM1's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

EXMceuticals Debt-to-Equity Historical Data

The historical data trend for EXMceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EXMceuticals Debt-to-Equity Chart

EXMceuticals Annual Data

Trend

Jun11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Debt-to-Equity

Get a 7-Day Free Trial

0.79

-0.71

EXMceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Debt-to-Equity	Get a 7-Day Free Trial															-1.29	-0.71	-0.71	-0.44	-0.65

Competitive Comparison of EXMceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, EXMceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EXMceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EXMceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where EXMceuticals's Debt-to-Equity falls into.

EXMceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

EXMceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.01	+	0.203)	/	-4.511
	=	-0.71

EXMceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.687	+	0.014)	/	-1.085
	=	-0.65

EXMceuticals (FRA:9OM1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

EXMceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of EXMceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

EXMceuticals (FRA:9OM1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EXMceuticals Inc (FRA:9OM1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

421 7th Avenue S.W., 30th Floor, Calgary, AB, CAN, T2P 4K9

Website

http://www.exmceuticals.com

EXMceuticals Inc is a bio-science company that believes in the potential health and wellness benefits of hemp and cannabis. EXM is an emerging player in the market, with ambition and potential to become the suppliers of highest-grade cannabis ingredients. It is creating an industrial-scale, GMP, Pharmaceutical Grade Extraction and Refining facility inside the European Union, near Lisbon Portugal. It has an existing and licensed cannabis R&D facility and pilot refinery in Lisbon Portugal. EXM is targeting the B2B marketplace and will supply pure ingredients and API's to the pharmaceutical, medicinal and wellness industry.

EXMceuticals (FRA:9OM1) Headlines

No Headlines